Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Osteogenesis ImperfectaOsteogenesis Imperfecta Type III
Interventions
DRUG

Bone marrow-derived mesenchymal stromal cells (MSCs)

Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.

All Listed Sponsors
lead

Emory University

OTHER

NCT05559801 - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) | Biotech Hunter | Biotech Hunter